Table 3 Cardiovascular risk factors of experimental groups after 15 weeks of treatment
Variables | C | PO |
|---|---|---|
Lee index (g/cm3) | 3.1 ± 0.1 | 2.9 ± 0.2 |
Adiposity index (%) | 2.9 ± 0.7 | 3.1 ± 0.7 |
Plama glucose (mg/dL) | 123.7 ± 22.1 | 127.9 ± 9.6 |
Plasma insulin (ng/mL) | 1.0 ± 0.2 | 1.1 ± 0.3 |
HOMA-IR | 0.28 ± 0.05 | 0.27 ± 0.08 |
Plasma cholesterol (mg/dL) | 58.1 ± 8.5 | 62.1 ± 6.6 |
Plasma triglycerides (mg/dL) | 32.6 ± 5.3 | 33.8 ± 10.6 |
LDL-C (mg/dL) | 14.0 ± 1.2 | 15.7 ± 1.5 |
HDL-C (mg/dL) | 22.9 ± 5.9 | 23.0 ± 1.8 |
Hepatic cholesterol (mg.g−1) | 5.9 ± 1.1 | 4.8 ± 1.6 |
Hepatic triglycerides (mg.g−1) | 23.2 ± 2.4 | 17.0* ± 2.0 |
Systolic blood pressure (mmHg) | 152.4 ± 21.8 | 150.7 ± 26.3 |
Heart Rate (bpm) | 392.4 ± 62.2 | 402.7 ± 67.5 |
Double product index (mmHg x bpm) | 60451.6 ± 16078.5 | 61586.5 ± 20209.6 |
Muscle mass index (mg.g−1) | 4.6 ± 0.6 | 5.0 ± 0.7 |
Cardiomyocytes diameter (μm) | 12.8 ± 0.8 | 13.1 ± 0.8 |